ClinicalTrials.gg
CompletedNCT00484289Updated Jun 24, 2013Results posted

A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

A Phase 3 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 39 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-06-24.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
24th of 63
217 · median 119
Started
2006
with 2 others
Phase 3
26 of 63
2 open now
Registered
16th of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 24th largest by enrollment, is one of 3 that started in 2006, is one of 26 in phase 3, and was the 16th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the safety of chronic use of abatacept in Japanese Subjects with Rheumatoid Arthritis (RA) having completed clinical studies IM101-071, IM101-034, and also Disease Modifying Anti-Rheumatic Drugs (DMARDs) failures with MTX intolerance.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participants who completed the 169 days, full study period of Phase II (IM101-071) and were not administered other biologics between completion of IM101-071 and registration of this long-term study.
  • The participants of the Phase I study (IM101-034), who received abatacept, except participants who were withdrawn from the study due to safety problems related to abatacept.
  • New subjects with MTX intolerance: rheumatoid arthritis (RA) patients to whom MTX cannot be administered for safety reasons and who present an inadequate response to disease-modifying antirheumatic drugs (DMARDs;excluding MTX) or biologics (new subjects with MTX intolerance: RA patients who present an inadequate response to DMARDs).

Exclusion criteria

Exclusion Criteria

  • Women of (WOCBP) who were unwilling or unable to use an acceptable method of .
  • Participants who have received non approved or biologics (other than abatacept from previous or ongoing studies in Japan) at registration.
  • Participants who have received treatment with any investigational drug within 56 days before registration or five half-lives (whichever is the longest).
  • Participants currently receiving treatment with leflunomide, mycophenolate mofetil, calcineurine inhibitors such as cyclosporine and tacrolimus, D-Penicillamine, Cyclophosphamide, or immunoadsorption columns.
  • The participants who completed Phase II (IM101-071) are not applicable in the following instances at time of registration: with active vasculitis, symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, breast cancer, or a history of cancer within the last 5 years, evidence of active or latent bacterial , viral infections, any serious or chronic, at risk of tuberculosis (TB), with any opportunistic infections, laboratory values of \< 8.5 g/dL, white blood cells (WBC) \< 3,000/mm\^3, \< 100,000/mm\^3, Serum creatinine > 2 times (ULN), Serum or aspartate aminotransferase > 2 times ULN.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Arm 1: Participants from Phase I study (IM101-034)

    Drug: Abatacept

  • Experimental
    Arm 2: Participants from Phase II study (IM101-071)

    Drug: Abatacept

  • Experimental
    Arm 3: New Participants with Methotrexate (MTX) Intolerance

    Drug: Abatacept

Interventions

  • Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.

    Also known as: Orencia®, BMS-188667

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs

    AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. Both subjective and objective AEs and SAEs are included.

    Time frame: From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).

  2. Number of Participants With Abnormal Laboratory Changes (ALC)

    The laboratory tests were analyses included enzyme, gastrointestinal, hematology, hepatobiliary, lipid, metabolic, nutritional, blood gas, microbiology, serology, protein, chemistry, renal, urinary tract, urinalyses, water, electrolyte and mineral investigations.

    Time frame: From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).

  3. Number of Participants With Vital Signs, Physical Examinations, and Electrocardiogram Findings That Were Considered to be AEs by the Investigator

    Time frame: At week 0, 2, 4; then once every 4 weeks up to 48 months; then once in every 3 months or 12 weeks to end of study (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).

Secondary outcomes

  1. Percentage of Participants With American College of Rheumatology (ACR 20) Response Over Time

    ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.

    Time frame: At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.

  2. Percentage of Participants With ACR 50 Response Over Time

    ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.

    Time frame: At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.

  3. Percentage of Participants With ACR 70 Response Over Time

    ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.

    Time frame: At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.

  4. Baseline (BL) and Postbaseline (PBL) Disease Activity Scores (DAS 28)

    The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (change of \> 5.1), low disease activity (change of ≤ 3.2) and remission (\< 2.6). Please see outcome 8 for change from BL data.

    Time frame: At BL (week 0), week 24, 48, 96, 144, and 192.

  5. Change From Baseline in DAS 28 Scores at Week 24, 48, 96, 144, and 192

    The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Please refer to outcome 7 for BL and PBL values.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  6. Number of Participants With DAS 28 Score Change ≥ 1.2 From Baseline at Weeks 24, 48, 96, 144, and 192

    The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score change ≥ 1.2 from BL were considered to have improvement.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  7. Number of Participants With Low Disease Activity Score (DAS 28 Score ≤ 3.2) at Weeks 24, 48, 96, 144, 192

    The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score ≤ 3.2 were considered to have low disease activity.

    Time frame: At weeks 24, 48, 96, 144, and 192.

  8. Number of Participants in Remission (DAS 28 Score < 2.6) at Weeks 24, 48, 96, 144, 192

    The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score \< 2.6 were considered to be in remission.

    Time frame: At weeks 24, 48, 96, 144, and 192.

  9. Percentage of Participants Who Achieved a Reduction of At Least 0.3 Units From Baseline in Health Assessment Questionnaire (HAQ) at Weeks 24, 48, 96, 144, 192

    The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from BL in HAQ.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  10. Baseline and Postbaseline Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Scores

    The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 14 for change from BL data.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  11. Change From Baseline in Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192

    The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \>3 points were considered clinically meaningful. Please see outcome 13 for BL and PBL values.

    Time frame: At baseline (week 0), weeks 24, 48, 96, 144, and 192.

  12. Baseline and Postbaseline Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Scores

    The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful. Please see outcome 14 for change from BL data.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  13. Change From Baseline in Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192

    The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 15 for BL and PBL values.

    Time frame: At BL (Week 0), weeks 24, 48, 96, 144, and 192.

  14. Baseline and Postbaseline C-reactive Protein (CRP) Levels

    CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease. Please see outcome 18 for change from BL data.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  15. Percentage Decrease in C-reactive Protein Levels From Baseline at Weeks 24, 48, 96, 144, and 192

    CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease, negative values indicate improvement. Percentage improvement from BL = (BL - PBL value) / BL value \* 100. Please refer to outcome 17 for BL and PBL values.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  16. Baseline and Postbaseline Rheumatoid Factor Levels

    Rheumatoid factor (RF or RhF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please see outcome 20 for change from BL data.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  17. Change From Baseline in Rheumatoid Factor Levels at Weeks 24, 48, 96, 144, and 192

    RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please refer to outcome 19 for BL and PBL values.

    Time frame: At BL (week 0), weeks 24, 48, 96, 144, and 192.

  18. Number of Participants Who Were Positive for Anti-abatacept and Anti-CTLA4-T Antibodies

    Validated enzyme-linked immunoassay (ELISA) method was used to measure anti-abatacept and anti-CTLA4-T antibody levels. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed.

    Time frame: At BL (week 0), weeks 24, 48, 72, 96, 120, 144, 168, and 192.

  19. Abatacept PK Parameter: Total Body Clearance

    Total body clearance is the rate and extent at which the drug is eliminated from the body. The clearance of a drug is used to understand the processes involved in drug elimination, distribution and metabolism.

    Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.

  20. Abatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State

    Area under the plasma concentration-time curve (AUCss) at steady state for each dosing interval was determined using the linear trapezoidal rule.

    Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.

  21. Abatacept PK Parameter: Maximum Serum Concentration at Steady State

    Maximum plasma concentration is the maximum observed serum drug concentration at steady state (Css max).

    Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.

  22. Abatacept PK Parameter: Minimum Plasma Concentration at Steady State

    Minimum Plasma Concentration (Cmin) is the minimum observed serum drug concentration at steady state.

    Time frame: Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.

07

Results

Posted Aug 9, 2012

Participant flow

Long Term Phase
Participant flow — Long Term Phase
MilestoneParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Started1317826
Completed1014210
Not completed33616
Withdrew: Adverse event1175
Withdrew: Withdrawal by subject076
Withdrew: Inadequate response274
Withdrew: Other reason051
Post Marketing Phase
Participant flow — Post Marketing Phase
MilestoneParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Started1014210
Completed1014110
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs

AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a cancer, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event. Both subjective and objective AEs and SAEs are included.

Time frame:
From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Reported as:
Number · participants
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to AEs
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
SAEs45014
Drug-related SAEs2269
AEs1317624
Drug-related AEs1316524
Discontinuation due to SAEs0145
Discontinuation due to AEs1185
Deaths010
SecondaryPercentage of Participants With American College of Rheumatology (ACR 20) Response Over Time

ACR 20 response requires a participant to have a 20% reduction in the number of swollen and tender joints, and a reduction of 20% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.

Time frame:
At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR 20) Response Over Time
percentage of participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 4; (n=13, 178,26)30.8 (9.1 to 61.4)29.2 (22.7 to 36.5)34.6 (17.2 to 55.7)
Week 12; (n=13, 178,24)76.9 (46.2 to 95.0)47.2 (39.7 to 54.8)58.3 (36.6 to 77.9)
Week 24; (n=13, 176, 23)76.9 (46.2 to 95.0)59.7 (52.0 to 67.0)78.3 (56.3 to 92.5)
Week 36; (n=13, 175, 20)69.2 (38.6 to 90.9)61.7 (54.1 to 68.9)90.0 (68.3 to 98.8)
Week 48; (n=13, 170, 18)61.5 (31.6 to 86.1)63.5 (55.8 to 70.8)88.9 (65.3 to 98.6)
Week 60; (n=13, 165, 17)69.2 (38.6 to 90.9)69.7 (62.1 to 76.6)94.1 (71.3 to 99.9)
Week 72; (n=13, 161, 17)84.6 (54.6 to 98.1)67.7 (59.9 to 74.8)94.1 (71.3 to 99.9)
Week 84; (n=13, 161, 17)61.5 (31.6 to 86.1)67.1 (59.2 to 74.3)100.0 (80.5 to 100.0)
Week 96; (n=13, 160, 17)69.2 (38.6 to 90.9)63.8 (55.8 to 71.2)82.4 (56.6 to 96.2)
Week 108; (n=13, 156, 15)53.8 (25.1 to 80.8)67.9 (60.0 to 75.2)100.0 (78.2 to 100.0)
Week 120; (n=13, 154, 15)69.2 (38.6 to 90.9)69.5 (61.6 to 76.6)100.0 (78.2 to 100.0)
Week 132; (n=13, 151, 14)61.5 (31.6 to 86.1)68.9 (60.8 to 76.2)100.0 (76.8 to 100.0)
Week 144; (n=12, 142, 13)58.3 (27.7 to 84.8)69.7 (61.5 to 77.1)84.6 (54.6 to 98.1)
Week 156; (n=11, 113, 12)63.6 (30.8 to 89.1)66.4 (56.9 to 75.0)100.0 (73.5 to 100.0)
Week 168; (n=10, 80, 8)80.0 (44.4 to 97.5)71.3 (60.0 to 80.8)100.0 (63.1 to 100.0)
Week 180; (n=8, 56, 4)62.5 (24.5 to 91.5)69.6 (55.9 to 81.2)100.0 (39.8 to 100.0)
Week 192; (n=3, 7, 1)66.7 (9.4 to 99.2)85.7 (42.1 to 99.6)100.0 (2.5 to 100.0)
SecondaryPercentage of Participants With ACR 50 Response Over Time

ACR 50 response requires a participant to have a 50% reduction in the number of swollen and tender joints, and a reduction of 50% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.

Time frame:
At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.
Reported as:
Number · percentage of participants
Percentage of Participants With ACR 50 Response Over Time
percentage of participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 4; (n=13, 178, 26)15.4 (1.9 to 45.4)6.2 (3.1 to 10.8)0 (0 to 13.2)
Week 12; (n=13, 178,24)38.5 (13.9 to 68.4)16.3 (11.2 to 22.6)29.2 (12.6 to 51.1)
Week 24; (n=13, 176, 23)30.8 (9.1 to 61.4)25.6 (19.3 to 32.7)47.8 (26.8 to 69.4)
Week 36; (n=13, 175, 20)38.5 (13.9 to 68.4)28.6 (22.0 to 35.9)50.0 (27.2 to 72.8)
Week 48; (n=13, 170, 18)15.4 (1.9 to 45.4)38.8 (31.5 to 46.6)72.2 (46.5 to 90.3)
Week 60; (n=13, 165, 17)30.8 (9.1 to 61.4)42.4 (34.8 to 50.3)58.8 (32.9 to 81.6)
Week 72; (n=13, 161, 17)46.2 (19.2 to 74.9)43.5 (35.7 to 51.5)70.6 (44.0 to 89.7)
Week 84; (n=13, 161, 17)38.5 (13.9 to 68.4)42.2 (34.5 to 50.3)70.6 (44.0 to 89.7)
Week 96; (n=13, 160, 17)23.1 (5.0 to 53.8)38.1 (30.6 to 46.1)58.8 (32.9 to 81.6)
Week 108; (n=13, 156, 15)23.1 (5.0 to 53.8)42.3 (34.4 to 50.5)66.7 (38.4 to 88.2)
Week 120; (n=13, 154, 15)46.2 (19.2 to 74.9)45.5 (37.4 to 53.7)93.3 (68.1 to 99.8)
Week 132; (n=13, 151, 14)38.5 (13.9 to 68.4)43.7 (35.7 to 52.0)85.7 (57.2 to 98.2)
Week 144; (n=12, 142, 13)25.0 (5.5 to 57.2)47.2 (38.8 to 55.7)69.2 (38.6 to 90.9)
Week 156; (n=11, 113, 12)36.4 (10.9 to 69.2)47.8 (38.3 to 57.4)83.3 (51.6 to 97.9)
Week 168; (n=10, 80, 8)30.0 (6.7 to 65.2)47.5 (36.2 to 59.0)87.5 (47.3 to 99.7)
Week 180; (n=8, 56, 4)12.5 (0.3 to 52.7)51.8 (38.0 to 65.3)75.0 (19.4 to 99.4)
Week 192; (n=3, 7, 1)66.7 (9.4 to 99.2)71.4 (29.0 to 96.3)100.0 (2.5 to 100.0)
SecondaryPercentage of Participants With ACR 70 Response Over Time

ACR 70 response requires a participant to have a 70% reduction in the number of swollen and tender joints, and a reduction of 70% in three of the following five parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant global assessment of pain, C-reactive protein, and degree of disability in Health Assessment Questionnaire score.

Time frame:
At weeks 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192.
Reported as:
Number · percentage of participants
Percentage of Participants With ACR 70 Response Over Time
percentage of participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 4; (n=13, 178, 26)7.7 (0.2 to 36.0)0 (0 to 2.1)0 (0 to 13.2)
Week 12; (n=13, 178, 24)7.7 (0.2 to 36.0)5.6 (2.7 to 10.1)8.3 (1.0 to 27.0)
Week 24; (n=13, 176, 23)7.7 (0.2 to 36.0)10.8 (6.6 to 16.3)21.7 (7.5 to 43.7)
Week 36; (n=13, 175, 20)15.4 (1.9 to 45.4)11.4 (7.1 to 17.1)20.0 (5.7 to 43.7)
Week 48; (n=13, 170, 18)15.4 (1.9 to 45.4)15.3 (10.2 to 21.6)27.8 (9.7 to 53.5)
Week 60; (n=13, 165, 17)15.4 (1.9 to 45.4)19.4 (13.7 to 26.3)29.4 (10.3 to 56.0)
Week 72; (n=13, 161, 17)15.4 (1.9 to 45.4)18.6 (12.9 to 25.5)23.5 (6.8 to 49.9)
Week 84; (n=13, 161, 17)7.7 (0.2 to 36.0)17.4 (11.9 to 24.1)23.5 (6.8 to 49.9)
Week 96; (n=13, 160, 17)7.7 (0.2 to 36.0)19.4 (13.6 to 26.4)23.5 (6.8 to 49.9)
Week 108; (n=13, 156, 15)7.7 (0.2 to 36.0)15.4 (10.1 to 22.0)33.3 (11.8 to 61.6)
Week 120; (n=13, 154, 15)7.7 (0.2 to 36.0)19.5 (13.5 to 26.6)46.7 (21.3 to 73.4)
Week 132; (n=13, 151, 14)0 (0 to 24.7)20.5 (14.4 to 27.9)42.9 (17.7 to 71.1)
Week 144; (n=12, 142, 13)0 (0 to 26.5)21.8 (15.3 to 29.5)23.1 (5.0 to 53.8)
Week 156; (n=11, 113, 12)0 (0 to 28.5)25.7 (17.9 to 34.7)33.3 (9.9 to 65.1)
Week 168; (n=10, 80, 8)0 (0 to 30.8)27.5 (18.1 to 38.6)62.5 (24.5 to 91.5)
Week 180; (n=8, 56, 4)0 (0 to 36.9)33.9 (21.8 to 47.8)50.0 (6.8 to 93.2)
Week 192; (n=3, 7, 1)0 (0 to 70.8)14.3 (0.4 to 57.9)100.0 (2.5 to 100.0)
SecondaryBaseline (BL) and Postbaseline (PBL) Disease Activity Scores (DAS 28)

The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (change of \> 5.1), low disease activity (change of ≤ 3.2) and remission (\< 2.6). Please see outcome 8 for change from BL data.

Time frame:
At BL (week 0), week 24, 48, 96, 144, and 192.
Reported as:
Mean · Units on a Scale
Baseline (BL) and Postbaseline (PBL) Disease Activity Scores (DAS 28)
Units on a ScaleParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24- BL (n=13, 176, 21)4.4 ± 1.04.8 ± 1.46.3 ± 1.0
Week 24- PBL (n=13, 176, 21)3.0 ± 1.13.2 ± 1.14.0 ± 1.9
Week 48- BL (n=13, 168, 18)4.4 ± 1.04.8 ± 1.46.3 ± 1.0
Week 48- PBL (n=13, 168, 18)3.0 ± 1.12.9 ± 1.13.5 ± 1.4
Week 96- BL (n=13, 159, 17)4.4 ± 1.04.8 ± 1.46.2 ± 1.0
Week 96- PBL (n=13, 159, 17)3.3 ± 1.02.8 ± 1.03.2 ± 1.0
Week 144- BL (n=12, 142, 13)4.3 ± 0.94.9 ± 1.46.3 ± 1.0
Week 144- PBL (n=12, 142, 13)3.0 ± 0.92.8 ± 1.03.2 ± 1.2
Week 192- BL (n=3, 7, 1)4.6 ± 1.65.4 ± 0.97.9 ± NA
Week 192- PBL (n=3, 7, 1)2.6 ± 1.23.1 ± 1.41.9 ± NA
SecondaryChange From Baseline in DAS 28 Scores at Week 24, 48, 96, 144, and 192

The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale of 100 mm. The DAS28 has numeric thresholds that define high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Please refer to outcome 7 for BL and PBL values.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · Units on a Scale
Change From Baseline in DAS 28 Scores at Week 24, 48, 96, 144, and 192
Units on a ScaleParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 21)-1.4 (-2.0 to -0.8)-1.7 (-1.8 to -1.5)-2.3 (-2.9 to -1.7)
Week 48 (n=13, 168, 18)-1.4 (-2.0 to -0.9)-1.9 (-2.1 to -1.7)-2.8 (-3.3 to -2.3)
Week 96 (n=13, 159, 17)-1.1 (-1.7 to -0.6)-2.0 (-2.3 to -1.8)-3.0 (-3.6 to -2.4)
Week 144 (n=12, 142, 13)-1.3 (-1.8 to -0.8)-2.1 (-2.3 to -1.9)-3.1 (-4.0 to -2.2)
Week 192 (n=3, 7, 1)-2.0 (-3.4 to -0.6)-2.3 (-3.6 to -1.1)-6.0 (NA to NA)
SecondaryNumber of Participants With DAS 28 Score Change ≥ 1.2 From Baseline at Weeks 24, 48, 96, 144, and 192

The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score change ≥ 1.2 from BL were considered to have improvement.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Number · participants
Number of Participants With DAS 28 Score Change ≥ 1.2 From Baseline at Weeks 24, 48, 96, 144, and 192
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 21)911317
Week 48 (n=13, 168, 18)811416
Week 96 (n=13, 159, 17)711116
Week 144 (n=12, 142, 13)610712
Week 192 (n=3, 7, 1)351
PrimaryNumber of Participants With Abnormal Laboratory Changes (ALC)

The laboratory tests were analyses included enzyme, gastrointestinal, hematology, hepatobiliary, lipid, metabolic, nutritional, blood gas, microbiology, serology, protein, chemistry, renal, urinary tract, urinalyses, water, electrolyte and mineral investigations.

Time frame:
From initiation of the study drug (31 Mar 2008) to data cutoff (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Reported as:
Number · participants
Number of Participants With Abnormal Laboratory Changes (ALC)
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Participants with Serious ALC001
Discontinuations due Serious ALC000
Participants with drug related Serious ALC001
Participants with ALC010
Discontinuations due ALC712519
Discontinuations due ALC610213
SecondaryNumber of Participants With Low Disease Activity Score (DAS 28 Score ≤ 3.2) at Weeks 24, 48, 96, 144, 192

The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score ≤ 3.2 were considered to have low disease activity.

Time frame:
At weeks 24, 48, 96, 144, and 192.
Reported as:
Number · participants
Number of Participants With Low Disease Activity Score (DAS 28 Score ≤ 3.2) at Weeks 24, 48, 96, 144, 192
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 21)9956
Week 48 (n=13, 168, 18)91057
Week 96 (n=13, 159, 17)61016
Week 144 (n=12, 142, 13)6957
Week 192 (n=3, 7, 1)231
SecondaryNumber of Participants in Remission (DAS 28 Score < 2.6) at Weeks 24, 48, 96, 144, 192

The DAS 28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, CRP levels, and participant assessment of disease activity measure on a visual analogue scale. Participants with DAS 28 score \< 2.6 were considered to be in remission.

Time frame:
At weeks 24, 48, 96, 144, and 192.
Reported as:
Number · participants
Number of Participants in Remission (DAS 28 Score < 2.6) at Weeks 24, 48, 96, 144, 192
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 21)6606
Week 48 (n=13, 168, 18)4755
Week 96 (n=13, 159, 17)3755
Week 144 (n=12, 142, 13)4713
Week 192 (n=3, 7, 1)221
SecondaryPercentage of Participants Who Achieved a Reduction of At Least 0.3 Units From Baseline in Health Assessment Questionnaire (HAQ) at Weeks 24, 48, 96, 144, 192

The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from BL in HAQ.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Reduction of At Least 0.3 Units From Baseline in Health Assessment Questionnaire (HAQ) at Weeks 24, 48, 96, 144, 192
percentage of participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 23)38.5 (13.9 to 68.4)39.2 (31.9 to 46.8)52.2 (30.6 to 73.2)
Week 48 (n=13, 170, 18)30.8 (9.1 to 61.4)41.2 (33.7 to 49.0)77.8 (52.4 to 93.6)
Week 96 (n=13, 160, 17)46.2 (19.2 to 74.9)47.5 (39.6 to 55.5)76.5 (50.1 to 93.2)
Week 144 (n=12, 142, 13)50.0 (21.1 to 78.9)48.6 (40.1 to 57.1)69.2 (38.6 to 90.9)
Week 192 (n=3, 7, 1)100.0 (29.2 to 100.0)85.7 (42.1 to 99.6)100.0 (2.5 to 100.0)
SecondaryBaseline and Postbaseline Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Scores

The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 14 for change from BL data.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · Units on a Scale
Baseline and Postbaseline Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Scores
Units on a ScaleParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24- BL (n=13, 176, 23)34.2 ± 14.530.3 ± 15.219.0 ± 12.5
Week 24- PBL (n=13, 176, 23)40.6 ± 12.638.5 ± 14.330.3 ± 17.1
Week 48- BL (n=13, 170, 18)34.2 ± 14.530.4 ± 15.220.1 ± 12.4
Week 48- PBL (n=13, 170, 18)40.9 ± 11.140.1 ± 13.737.1 ± 14.0
Week 96- BL (n=13, 160, 17)34.2 ± 14.529.8 ± 15.219.9 ± 12.7
Week 96- PBL (n=13, 160, 17)38.7 ± 12.640.3 ± 13.237.5 ± 13.5
Week 144- BL (n=12, 142, 13)32.9 ± 14.430.6 ± 15.121.1 ± 14.0
Week 144- PBL (n=12, 142, 13)37.8 ± 14.539.2 ± 13.732.9 ± 14.2
Week 192- BL (n=3, 7, 1)24.6 ± 10.922.8 ± 12.212.5 ± NA
Week 192- PBL (n=3, 7, 1)30.4 ± 24.838.5 ± 16.137.0 ± NA
SecondaryChange From Baseline in Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192

The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \>3 points were considered clinically meaningful. Please see outcome 13 for BL and PBL values.

Time frame:
At baseline (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · Units on a Scale
Change From Baseline in Physical Component Summary (PCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192
Units on a ScaleParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 23)6.5 (0 to 13.0)8.2 (6.4 to 10.0)11.3 (5.2 to 17.5)
Week 48 (n=13, 170, 18)6.7 (0.3 to 13.1)9.7 (7.7 to 11.7)17.1 (11.1 to 23.0)
Week 96 (n=13, 160, 17)4.5 (-4.5 to 13.6)10.4 (8.5 to 12.4)17.6 (9.7 to 25.5)
Week 144 (n=12, 142, 13)4.8 (-5.3 to 14.9)8.6 (6.6 to 10.6)11.8 (4.4 to 19.1)
Week 192 (n=3, 7, 1)5.7 (-79.9 to 91.4)15.7 (0.7 to 30.8)24.6 (NA to NA)
SecondaryBaseline and Postbaseline Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Scores

The SF-36 covers 8 health dimensions including 4 physical subscales (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from 0 to 100, with a higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful. Please see outcome 14 for change from BL data.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · Units on a Scale
Baseline and Postbaseline Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Scores
Units on a ScaleParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24- BL (n=13, 176, 23)41.6 ± 12.448.6 ± 8.541.7 ± 9.8
Week 24- PBL (n=13, 176, 23)45.2 ± 8.951.2 ± 7.549.5 ± 10.5
Week 48- BL (n=13, 170, 18)41.6 ± 12.448.6 ± 8.543.2 ± 9.6
Week 48- PBL (n=13, 170, 18)49.0 ± 8.051.6 ± 8.149.9 ± 7.5
Week 96- BL (n=13, 160, 17)41.6 ± 12.448.6 ± 8.543.6 ± 9.8
Week 96- PBL (n=13, 160, 17)49.9 ± 7.250.6 ± 7.551.6 ± 8.2
Week 144- BL (n=12, 142, 13)41.6 ± 13.048.5 ± 8.642.2 ± 9.4
Week 144- PBL (n=12, 142, 13)51.1 ± 7.650.6 ± 7.351.1 ± 8.4
Week 192- BL (n=3, 7, 1)45.7 ± 20.445.4 ± 8.137.1 ± NA
Week 192- PBL (n=3, 7, 1)60.7 ± 6.152.4 ± 12.569.3 ± NA
SecondaryChange From Baseline in Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192

The SF-36 covers 8 health dimensions including 4 physical (physical function, role functioning \[physical\], bodily pain, and general health) and 4 mental subscales (vitality, social function, role emotional, and mental health). All subscales were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, higher score indicating better quality of life. Improvements of \> 3 points were considered clinically meaningful.Please see outcome 15 for BL and PBL values.

Time frame:
At BL (Week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · Units on a Scale
Change From Baseline in Mental Component Summary (MCS) of Health-Related Quality of Life (SF-36) Score at Weeks 24, 48, 96, 144, and 192
Units on a ScaleParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 23)3.6 (-1.3 to 8.6)2.6 (1.5 to 3.7)7.7 (1.7 to 13.8)
Week 48 (n=13, 170, 18)7.4 (2.5 to 12.3)3.0 (1.7 to 4.3)6.7 (1.4 to 11.9)
Week 96 (n=13, 160, 17)8.3 (2.0 to 14.6)2.1 (0.7 to 3.4)8.0 (1.9 to 14.2)
Week 144 (n=12, 142, 13)9.5 (3.4 to 15.6)2.1 (0.8 to 3.5)8.9 (1.9 to 15.9)
Week 192 (n=3, 7, 1)15.0 (-49.5 to 79.6)7.0 (-5.2 to 19.3)32.1 (NA to NA)
SecondaryBaseline and Postbaseline C-reactive Protein (CRP) Levels

CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease. Please see outcome 18 for change from BL data.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · mg/dL
Baseline and Postbaseline C-reactive Protein (CRP) Levels
mg/dLParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24- BL (n=13, 176, 21)1.8 ± 2.82.3 ± 2.23.9 ± 3.1
Week 24- PBL (n=13, 176, 21)0.7 ± 0.70.8 ± 1.31.9 ± 2.5
Week 48- BL (n=13, 168, 18)1.8 ± 2.82.2 ± 2.14.1 ± 3.1
Week 48- PBL (n=13, 168, 18)1.1 ± 2.10.6 ± 1.10.9 ± 1.3
Week 96- BL (n=13, 159, 17)1.8 ± 2.82.3 ± 2.24.1 ± 3.2
Week 96- PBL (n=13, 159, 17)0.9 ± 1.30.5 ± 0.91.0 ± 1.0
Week 144- BL (n=12, 142, 13)1.9 ± 2.92.4 ± 2.24.2 ± 3.4
Week 144- PBL (n=12, 142, 13)1.2 ± 1.40.6 ± 1.50.6 ± 0.6
Week 192- BL (n=3, 7, 1)4.6 ± 5.41.7 ± 1.28.4 ± NA
Week 192- PBL (n=3, 7, 1)1.4 ± 1.70.8 ± 1.60.2 ± NA
SecondaryPercentage Decrease in C-reactive Protein Levels From Baseline at Weeks 24, 48, 96, 144, and 192

CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA) and is a core component of the ACR scoring system. CRP was evaluated from serum samples. Increasing levels indicate increasing level of disease, negative values indicate improvement. Percentage improvement from BL = (BL - PBL value) / BL value \* 100. Please refer to outcome 17 for BL and PBL values.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · percentage improvement
Percentage Decrease in C-reactive Protein Levels From Baseline at Weeks 24, 48, 96, 144, and 192
percentage improvementParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 21)-18.4 (-147.8 to 111.1)30.5 (-0.4 to 61.4)60.2 (42.7 to 77.7)
Week 48 (n=13, 168, 18)12.0 (-35.9 to 59.9)31.9 (8.7 to 55.1)77.8 (65.2 to 90.3)
Week 96 (n=13, 159, 17)-3.3 (-77.9 to 71.3)40.5 (21.8 to 59.1)70.1 (51.0 to 89.2)
Week 144 (n=12, 142, 13)-71.9 (-188.7 to 44.9)-39.3 (-191.5 to 113.0)79.9 (68.0 to 91.7)
Week 192 (n=3, 7, 1)67.9 (52.0 to 83.7)39.7 (-83.2 to 162.6)97.4 (NA to NA)
SecondaryBaseline and Postbaseline Rheumatoid Factor Levels

Rheumatoid factor (RF or RhF) is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please see outcome 20 for change from BL data.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · IU/mL
Baseline and Postbaseline Rheumatoid Factor Levels
IU/mLParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24- BL (n=13, 176, 21)200.2 ± 343.8214.3 ± 383.3630.8 ± 873.4
Week 24- PBL (n=13, 176, 21)127.5 ± 191.6141.0 ± 289.2573.9 ± 897.2
Week 48- BL (n=13, 168, 18)200.2 ± 343.8217.3 ± 389.7560.9 ± 893.0
Week 48- PBL (n=13, 168, 18)139.9 ± 241.8149.5 ± 288.4288.3 ± 482.8
Week 96- BL (n=13, 159, 17)200.2 ± 343.8215.9 ± 393.9590.9 ± 911.1
Week 96- PBL (n=13, 159, 17)186.9 ± 339.4151.0 ± 285.8216.8 ± 329.2
Week 144- BL (n=12, 142, 13)205.6 ± 358.5229.0 ± 412.6639.4 ± 990.8
Week 144- PBL (n=12, 142, 13)211.3 ± 359.8173.7 ± 360.8361.6 ± 663.9
Week 192- BL (n=3, 7, 1)314.3 ± 455.3253.7 ± 307.62800.0 ± NA
Week 192- PBL (n=3, 7, 1)315.0 ± 307.0348.4 ± 521.6197.0 ± NA
SecondaryChange From Baseline in Rheumatoid Factor Levels at Weeks 24, 48, 96, 144, and 192

RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis. It is an antibody against the Fc portion of Immunoglobulin (Ig)G, which is itself an antibody. RF and IgG join to form immune complexes which contribute to the disease process. RF levels are considered positive if value is \>20 and considered negative if value is \<20. Please refer to outcome 19 for BL and PBL values.

Time frame:
At BL (week 0), weeks 24, 48, 96, 144, and 192.
Reported as:
Mean · IU/mL
Change From Baseline in Rheumatoid Factor Levels at Weeks 24, 48, 96, 144, and 192
IU/mLParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Week 24 (n=13, 176, 21)-72.6 (-197.5 to 52.2)-73.2 (-102.8 to -43.7)-56.9 (-149.5 to 35.7)
Week 48 (n=13, 168, 18)-60.2 (-137.9 to 17.4)-67.8 (-100.4 to -35.2)-272.6 (-494.0 to -51.2)
Week 96 (n=13, 159, 17)-13.2 (-63.3 to 36.8)-64.9 (-103.3 to -26.6)-374.1 (-704.9 to -43.2)
Week 144 (n=12, 142, 13)5.7 (-43.0 to 54.4)-55.3 (-97.2 to -13.3)-277.8 (-708.2 to 152.7)
Week 192 (n=3, 7, 1)0.7 (-471.3 to 472.7)94.7 (-122.5 to 311.9)-2603 (NA to NA)
SecondaryNumber of Participants Who Were Positive for Anti-abatacept and Anti-CTLA4-T Antibodies

Validated enzyme-linked immunoassay (ELISA) method was used to measure anti-abatacept and anti-CTLA4-T antibody levels. For anti-abatacept antibody ELISA, a sample was considered seropositive if it had a titer of 400 or greater and if immunodepletion was observed. The responses that were negative in initial screen were reported as seronegative with a value of \< 400. A sample was considered positive in CTLA4-T antibody ELISA if it had a titer of 25 or greater and if immunodepletion was observed.

Time frame:
At BL (week 0), weeks 24, 48, 72, 96, 120, 144, 168, and 192.
Reported as:
Number · participants
Number of Participants Who Were Positive for Anti-abatacept and Anti-CTLA4-T Antibodies
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Positive for anti-abatacept antibody2192
Positive for anti-CTLA4-T antibody0191
SecondaryAbatacept PK Parameter: Total Body Clearance

Total body clearance is the rate and extent at which the drug is eliminated from the body. The clearance of a drug is used to understand the processes involved in drug elimination, distribution and metabolism.

Time frame:
Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Reported as:
Median · L/day
Abatacept PK Parameter: Total Body Clearance
L/dayAll Participants From IM101-129 Study
Abatacept PK Parameter: Total Body Clearance0.306 ± 0.098
SecondaryAbatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State

Area under the plasma concentration-time curve (AUCss) at steady state for each dosing interval was determined using the linear trapezoidal rule.

Time frame:
Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Reported as:
Median · µg*h/mL
Abatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State
µg*h/mLAll Participants From IM101-129 Study
Abatacept PK Parameter: Area Under the Serum Concentration-time Curve at Steady State42959.94 ± 12763.45
SecondaryAbatacept PK Parameter: Maximum Serum Concentration at Steady State

Maximum plasma concentration is the maximum observed serum drug concentration at steady state (Css max).

Time frame:
Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Reported as:
Median · µg/mL
Abatacept PK Parameter: Maximum Serum Concentration at Steady State
µg/mLAll Participants From IM101-129 Study
Abatacept PK Parameter: Maximum Serum Concentration at Steady State241.62 ± 73.96
SecondaryAbatacept PK Parameter: Minimum Plasma Concentration at Steady State

Minimum Plasma Concentration (Cmin) is the minimum observed serum drug concentration at steady state.

Time frame:
Samples were collected predose at week 8, 12, 16, 24; end of infusion at week 12; and at week 13-15 visits.
Reported as:
Median · µg/mL
Abatacept PK Parameter: Minimum Plasma Concentration at Steady State
µg/mLAll Participants From IM101-129 Study
Abatacept PK Parameter: Minimum Plasma Concentration at Steady State26.14 ± 23.10
PrimaryNumber of Participants With Vital Signs, Physical Examinations, and Electrocardiogram Findings That Were Considered to be AEs by the Investigator
Time frame:
At week 0, 2, 4; then once every 4 weeks up to 48 months; then once in every 3 months or 12 weeks to end of study (27 Dec 2010). The overall mean duration of exposure to the study drug was approximately 3 years (34.3 ± 10.7 months).
Reported as:
Number · participants
Number of Participants With Vital Signs, Physical Examinations, and Electrocardiogram Findings That Were Considered to be AEs by the Investigator
participantsParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
Blood pressure increased22712
Blood pressure decreased1111
Blood pressure diastolic decreased070
Blood pressure systolic increased032
Weight decreased050
Weight increased031
Body temperature decreased030
Body temperature increased020
Blood pressure systolic decreased111
Blood pressure diastolic increased010
Electrocardiogram abnormal010
Electrocardiogram ST segment depression010
Electrocardiogram ST-T segment abnormal010
Heart rate increased020
Heart rate decreased010

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants From Phase I Study (IM101-034); Abatacept 10mg/kg—4/13 (30.8%)13/13 (100%)
Participants From Phase II Study(IM101-071); Abatacept 10mg/kg—50/178 (28.1%)176/178 (98.9%)
New Participants With MTX Intolerance; Abatacept 10 mg/kg—14/26 (53.8%)24/26 (92.3%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
CholelithiasisHepatobiliary disorders1/131/1780/26
Arthritis bacterialInfections and infestations1/130/1780/26
GastroenteritisInfections and infestations1/131/1780/26
Femur fractureInjury, poisoning and procedural complications1/131/1780/26
Rib fractureInjury, poisoning and procedural complications1/130/1780/26
ArthralgiaMusculoskeletal and connective tissue disorders1/130/1780/26
Foot deformityMusculoskeletal and connective tissue disorders1/134/1780/26
OsteoarthritisMusculoskeletal and connective tissue disorders1/131/1782/26
DeafnessEar and labyrinth disorders0/130/1781/26
CataractEye disorders0/131/1781/26
Most frequent other events
Showing 10 of 105
Most frequent other events
EventParticipants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kg
NasopharyngitisInfections and infestations8/13103/17812/26
Blood pressure increasedInvestigations2/1327/17812/26
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders5/1328/1782/26
StomatitisGastrointestinal disorders4/1346/1783/26
CystitisInfections and infestations4/1311/1780/26
White blood cell count increasedInvestigations1/1329/1787/26
White blood cells urine positiveInvestigations3/1318/1783/26
Lymphocyte count decreasedInvestigations1/1335/1785/26
ConstipationGastrointestinal disorders0/1321/1785/26
Alanine aminotransferase increasedInvestigations2/1329/1782/26

Baseline characteristics

Age Continuous
Age Continuous(years)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
Mean52.8 ± 11.653.2 ± 11.557.8 ± 10.653.8 ± 11.4
Age, Customized
Age, Customized(participants)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
20 - 29 years1708
30 - 39 years213116
40 - 49 years039544
50 - 59 years670783
≥ 60 years4491366
Sex: Female, Male
Sex: Female, Male(Participants)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
Female1214619177
Male132740
Weight
Weight(kg)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
Mean55.2 ± 9.756.9 ± 9.453.9 ± 10.856.5 ± 9.6
Duration of Rheumatoid Arthritis
Duration of Rheumatoid Arthritis(participants)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
<= 2 years0 ± 9.024 ± 7.32 ± 10.126 ± 7.9
>2 to <= 5 years245451
> 5 to <= 10 years2571271
> 10 years952869
American College of Rheumatology (ACR) Functional Status Classification
American College of Rheumatology (ACR) Functional Status Classification(participants)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
Class I029029
Class II1211217141
Class III137947
Class IV0000
Number of Tender Joints
Number of Tender Joints(joints)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
Mean8.4 ± 5.214.3 ± 11.222.7 ± 13.314.9 ± 11.6
Number of Swollen Joints
Number of Swollen Joints(joints)Participants From Phase I Study (IM101-034); Abatacept 10mg/kgParticipants From Phase II Study(IM101-071); Abatacept 10mg/kgNew Participants With MTX Intolerance; Abatacept 10 mg/kgTotal
Mean9.1 ± 4.711.6 ± 8.717.2 ± 10.012.1 ± 8.9

9 further baseline measures are reported on the registry.

08

Study locations

39 sites
  • Local Institution
    Nagoya-Shi, Aichi 460-0001, Japan
  • Local Institution
    Nagoya, Aichi 466-8550, Japan
  • Local Institution
    Goshogawara-Shi, Aomori 037-0053, Japan
  • Local Institution
    Chiba-Shi, Chiba, Japan
  • Local Institution
    Fukui-Shi, Fukui 910-0041, Japan
  • Local Institution
    Fukui-Shi, Fukui 9100067, Japan
  • Local Institution
    Fukui-Shi, Fukui 9103133, Japan
  • Local Institution
    Fukuoka-Shi, Fukuoka 810-0065, Japan
  • Local Institution
    Fukuoka-Shi, Fukuoka 812-0025, Japan
  • Local Institution
    Kitakyushu-Shi, Fukuoka 807-8555, Japan
  • Local Institution
    Higashi-Hiroshima-Shi, Hiroshima 739-0002, Japan
  • Local Institution
    Sapporo City, Hokkaido 060-8648, Japan
  • Local Institution
    Sapporo-City, Hokkaido 060-0001, Japan
  • Local Institution
    Sapporo-City, Hokkaido 060-8604, Japan
  • Local Institution
    Kanzaki-Gun, Hyogo 679-2414, Japan
  • Local Institution
    Kato-Gun, Hyogo 673-1462, Japan
  • Local Institution
    Hitachi-Shi, Ibaraki 316-0035, Japan
  • Local Institution
    Tsukuba-Shi, Ibaraki 305-0005, Japan
  • Local Institution
    Sagamihara-Shi, Kanagawa 228-8522, Japan
  • Local Institution
    Sendai-Shi, Miyagi 981-0911, Japan
  • Local Institution
    Sendai-Shi, Miyagi 982-0032, Japan
  • Local Institution
    Sendai, Miyagi, Japan
  • Local Institution
    Nagano-Shi, Nagano 380-8582, Japan
  • Local Institution
    Tsukubo-Gun, Okayama 701-0304, Japan
  • Local Institution
    Kawachinagano-Shi, Osaka 86-0008, Japan
  • Local Institution
    Ureshino-Shi, Saga 843-0301, Japan
  • Local Institution
    Iruma-Gun, Saitama 350-0495, Japan
  • Local Institution
    Kawagoe-Shi, Saitama 350-8550, Japan
  • Local Institution
    Kitamoto-Shi, Saitama 364-0026, Japan
  • Local Institution
    Hamamatsu-Shi, Shizuoka 430-0906, Japan
  • Local Institution
    Kawachigun, Tochigi 329-1104, Japan
  • Local Institution
    Shimotsuke-Shi, Tochigi 3290498, Japan
  • Local Institution
    Arakawa-Ku, Tokyo 116-0011, Japan
  • Local Institution
    Bunkyo-Ku, Tokyo 113-0022, Japan
  • Local Institution
    Bunkyo-Ku, Tokyo 113-8519, Japan
  • Local Institution
    Setagaya-Ku, Tokyo 155-0032, Japan
  • Local Institution
    Shinjuku-Ku, Tokyo 162-0054, Japan
  • Local Institution
    Takaoka-Shi, Toyama 933-8525, Japan
  • Local Institution
    Chiba-Shi, 260-0801, Japan
09

References and documents

Publications

  • Takeuchi T, Matsubara T, Urata Y, Suematsu E, Ohta S, Honjo S, Abe T, Yamamoto A, Miyasaka N; Japan Abatacept Study Group. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2014 Sep;24(5):744-53. doi: 10.3109/14397595.2014.899179. Epub 2014 Apr 23. PubMed 24754273 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2007
First posted
Jun 8, 2007
Start
Dec 2006
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Aug 9, 2012
Last update
Jun 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00484289
Responsible party
Sponsor
First posted
Jun 8, 2007
Start date
Dec 2006
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Aug 9, 2012
Last update
Jun 24, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion